Pricing Log in Create free account

Grifols, S.A. (GRFS) vs Organon & Co. (OGN)

Grifols, S.A. and Organon & Co. are both Drug Manufacturers General companies. Organon & Co. is the larger, with a market value of $3.6B against $2.2B — 1.7× the size. Organon & Co. trades at the lower P/E: 17.3× against 18.2×. Grifols, S.A. grew revenue faster over the last twelve months: 10.9% against −3.21%. Grifols, S.A. has the higher net margin (6.02% vs 3.49%) and the lower return on invested capital (4.76% vs 6.26%). Both pay a dividend; Grifols, S.A. yields more (1.12% vs 0.58%). Across the 23 metrics below, Grifols, S.A. leads on 12 and Organon & Co. on 11.

Valuation

Metric GRFS OGN Drug Manufacturers General median
P/E 18.23 17.29 26.51
P/S 0.65 0.60 3.49
P/B 0.60 3.04 5.28
Price to free cash flow 7.65 6.35 21.67
EV/EBITDA 8.40 7.51 14.73
EV/Sales 1.77 1.76 4.15
Earnings yield 5.49% 5.78% 2.41%
Free cash flow yield 13.08% 15.75% 4.07%

Profitability

Metric GRFS OGN Drug Manufacturers General median
Gross margin 37.55% 53.12% 73.01%
Operating margin 16.69% 13.63% 18.34%
Net margin 6.02% 3.49% 7.31%
Free cash flow margin 8.51% 9.38% 18.56%
Return on equity 5.80% 20.30% 5.80%
Return on assets 2.28% 1.58% 2.28%
Return on invested capital 4.76% 6.26% 6.26%

Growth

Metric GRFS OGN Drug Manufacturers General median
Revenue growth (TTM) 10.87% (3.21%) 6.72%
EPS growth (last fiscal year) 168.00% (78.38%) 21.81%
Revenue growth, 5-year CAGR 6.89% (0.99%) 4.75%
Net income growth, 5-year CAGR (8.43%) (38.70%) 0.00%

Health

Metric GRFS OGN Drug Manufacturers General median
Debt to equity 1.12 7.17 0.62
Current ratio 2.33 2.02 1.39
Net debt to EBITDA 5.19 5.62 1.15

Dividend

Metric GRFS OGN Drug Manufacturers General median
Dividend yield 1.12% 0.58% 2.32%
Payout ratio 0.20 0.11 0.59

Size

Metric GRFS OGN Drug Manufacturers General median
Market cap 2.18b 3.62b 129.04b

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack